Dr. Weber on Nivolumab in the Adjuvant Setting for Melanoma
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the use of nivolumab (Opdivo) in the adjuvant setting for the treatment of patients with melanoma.
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the use of nivolumab (Opdivo) in the adjuvant setting for the treatment of patients with melanoma.
According to Weber, nivolumab as an adjuvant therapy for patients with high-risk melanoma was well tolerated. A third of the patients relapsed after 5 years, which was considered an improvement, explains Weber.
